Antidepressant Medications

Antidepressant medications are a class of drugs used to treat depressive and several other psychiatric disorders. They are grouped by their predominant pharmacological action — for example selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), tricyclic antidepressants, and monoamine oxidase inhibitors — and most act, at least initially, by increasing the availability of monoamine neurotransmitters in the brain.

Definition

Antidepressants (antidepressive agents) are medications indicated principally for depressive disorders that act mainly on monoaminergic and related neurotransmitter systems, conventionally grouped into classes by their primary pharmacological mechanism.

Scope

This entry describes the major classes of antidepressants, their broad mechanisms of action, and the high-level evidence on their comparative efficacy and acceptability as drawn from systematic reviews. It is a reference and educational overview of the drug class as a topic; it contains no dosing and is not a guide to prescribing or to individual treatment decisions.

Core questions

• What are the main classes of antidepressants, and how are they distinguished?
• What is their broad mechanism of action, and why is the clinical response delayed relative to their immediate biochemical effects?
• What does high-level evidence show about their comparative efficacy and acceptability?

Key concepts

• Selective serotonin reuptake inhibitors (SSRIs)
• Serotonin-noradrenaline reuptake inhibitors (SNRIs)
• Tricyclic antidepressants
• Monoamine oxidase inhibitors
• Monoamine hypothesis of depression
• Efficacy versus acceptability (tolerability)
• Delayed onset of clinical response
• Network meta-analysis as comparative evidence

Mechanisms

Most established antidepressants increase synaptic availability of monoamine neurotransmitters — serotonin, noradrenaline, and in some cases dopamine — by inhibiting their reuptake or breakdown. This observation underlies the historical monoamine hypothesis of depression. However, the clinical antidepressant effect typically emerges over weeks, far slower than the immediate rise in neurotransmitter levels, which has led to mechanistic accounts emphasising downstream adaptations such as changes in receptor sensitivity, neuroplasticity, and neurotrophic signalling rather than monoamine elevation alone.

Clinical relevance

Antidepressants are among the most widely studied and prescribed psychiatric treatments, and understanding their classes and evidence base supports critical reading of the treatment literature. This entry describes the drug class for reference and education only; it provides no dosing and is not a substitute for prescribing decisions made by qualified clinicians using current guidelines.

Evidence & guidelines

A large network meta-analysis of 21 antidepressants for acute major depressive disorder in adults found that all examined drugs were more efficacious than placebo, with differences between drugs in efficacy and in acceptability (a proxy for tolerability and continuation). Pragmatic evidence such as the STAR*D study shows that many patients do not remit on a first agent and that sequential strategies are often needed. Treatment selection, sequencing, and monitoring follow current clinical guidelines and are outside the scope of this reference entry.

History

The first antidepressants — the monoamine oxidase inhibitor iproniazid and the tricyclic imipramine — emerged from serendipitous clinical observations in the 1950s, and their effects on monoamines gave rise to the monoamine hypothesis. The introduction of SSRIs from the late 1980s, designed for greater selectivity and tolerability, broadened antidepressant use, and subsequent decades produced SNRIs and other agents alongside large comparative-effectiveness studies.

Debates

How clinically meaningful are the differences between antidepressants?

Although network meta-analysis finds all studied antidepressants more efficacious than placebo and identifies differences between them, debate continues over the size and clinical importance of those differences and over how to weigh efficacy against acceptability in choosing an agent.

Is the monoamine hypothesis sufficient?

The delay between antidepressants' immediate effects on monoamines and their clinical benefit, together with newer agents acting on other systems, has led to debate over the adequacy of the monoamine hypothesis and to interest in neuroplasticity-based and other mechanisms.

Seminal works

• cipriani-2018
• rush-stard-2006
• kupfer-2012

Frequently asked questions

How do antidepressants work?

Most increase the availability of monoamine neurotransmitters such as serotonin and noradrenaline in the brain. Because clinical improvement usually takes weeks, researchers think the therapeutic effect involves slower downstream adaptations — changes in receptors and neuroplasticity — rather than the immediate rise in neurotransmitter levels alone.

Are some antidepressants clearly better than others?

A large network meta-analysis found all studied antidepressants more effective than placebo for acute depression in adults, with modest differences between drugs in efficacy and acceptability. There is no single best drug for everyone, and choice depends on clinical judgement; this entry does not recommend specific medications.